Luckett, Emma S.
Abakkouy, Yasmina
Reinartz, Mariska
Adamczuk, Katarzyna
Schaeverbeke, Jolien
Verstockt, Sare
De Meyer, Steffi
Van Laere, Koen
Dupont, Patrick
Cleynen, Isabelle
Vandenberghe, Rik
Article History
Received: 25 January 2022
Accepted: 8 September 2022
First Online: 23 September 2022
Declarations
:
: The protocol was approved by the Ethics Committee University Hospitals Leuven. All participants provided written informed consent in accordance with the declaration of Helsinki.
: Not applicable.
: RV has received research grants from Research Foundation—Flanders (FWO) and KU Leuven, has had a clinical trial agreement for phase 1 and 2 study between University Hospitals Leuven and GE-HC, has received a non-financial support from GE-HC (provision of <sup>18</sup>F-Flutemetamol for conduct of investigator-driven trial free of cost), and has a clinical trial agreement (local principal investigator) between University Hospitals Leuven and Biogen, J&J, NovoNordisk, Roche, and UCB.KVL has received research grants from FWO and KU Leuven, has clinical trial agreements through University Hospitals Leuven/KU Leuven and J&J, Merck, BMS, GE Healthcare, CHDI, Cerveau, Eikonizo, Lundbeck, UCB and Curasen.ESL, YA, MR, KA, JS, SV, SDM, PD, and IC have no disclosers.